Account
New to ADSS? Open an
account now to get started.
Already have an account?
Add funds to your ADSS account
Account
New to ADSS? Open an
account now to get started.
Add funds to your ADSS account
News
Friday, November 07, 2025
What’s happening: Shares of AstraZeneca gained on Thursday after the company released its results for the third quarter.
What happened: The drugmaker posted better-than-expected sales and earnings results for the latest quarter.
Despite the beat, AstraZeneca maintained its forecast for the full year, limiting the overall gains in the stock.
How were the results: The British pharmaceutical giant posted low double-digit sales growth for the three months ended September 30.
Why it matters: Strong sales of cancer and cardiovascular drugs helped AstraZeneca report upbeat results for the third quarter.
AstraZeneca’s cancer business represented 44% of overall sales, surging 19% to $6.64 billion. Cardiovascular, renal, and metabolism sales accounted for 21% of total sales, which grew by 2% to $3.22 billion. Respiratory & Immunology sales jumped 15% to $2.26 billion in the third quarter, while Rare Disease drug sales rose by 12% to $2.42 billion.
US sales rose 9% to $6.55 billion for the recent quarter, while revenues from China gained 6% to $1.76 billion.
AstraZeneca is looking to expand in the US and seeks a drug pricing deal to offset tariff pressures. The US accounted for more than 40% of the company’s overall sales in 2024.
The company announced signing an agreement last month to cut prices in the US for some of its prescription drugs after disclosing an investment plan of $50 billion in July.
“The strong underlying momentum across our business through the first nine months of the year sets us up well to sustain growth through 2026 and has us on track to deliver our 2030 ambition,” CEO Pascal Soriot said. Last year, AstraZeneca announced a bold ambition to reach $80 billion in total revenues by 2030.
Management reaffirmed its revenue and earnings growth guidance of high single-digit percentage and low double-digit percentage for 2025.
How shares responded: AstraZeneca’s shares gained 3.2% to close at $83.77 on Thursday following the release of its quarterly results. The stock has added around 27% year to date.
What to watch: Investors will continue monitoring AstraZeneca’s new launches, including a blood pressure drug, to offset patent expiries like for diabetes and heart treatment.
Context: The CAD/USD forex pair rose this morning as investors digested the latest economic data.
Details: Data released on Thursday showed that Canada’s Ivey Purchasing Managers Index declined to 52.4 in October, from 59.8 in the previous month. The figure also missed market estimates of 55.2. However, the latest reading signalled the sixth month of expansion, indicating overall growth in economic activity.
Strength in the price of crude oil, one of Canada’s major exports, provided a boost to the loonie. WTI crude oil prices gained 0.4% to $59.66 a barrel this morning.
Weakness in the US dollar lent further support to the CAD/USD forex pair. The US dollar index, which measures the greenback’s performance versus a basket of major peers, fell around 0.5% to 99.70.
The CAD/USD pair edged higher to 1.4116 this morning.
What to watch: Investors await the release of economic data on Canada’s unemployment rate (1730 UAE Time), employment change (1730 UAE Time) and average hourly wages (1730 UAE Time) today.
Analysts expect Canada’s unemployment rate to remain at 7.1% in October, unchanged from the previous month. Canada’s employment, which climbed by 60,400 in September following a 65,500 decline in the previous month, is expected to decline by 2,500 in October. Canada’s average hourly wages, which rose by 3.3% year-over-year to C$36.78 in September compared to a 3.2% gain in August, are expected to surge again by 3.3% in October.
Other Markets: US trading indices closed lower on Thursday, with the Dow Jones index, S&P 500 and Nasdaq 100 down by 0.84%, 1.12% and 1.91%, respectively.
Russia said it was close to capturing the city of Pokrovsk in eastern Ukraine. The news sent the RUB/USD pair higher in forex trading this morning.
Japan’s household spending grew by 1.8% year-over-year in September. This marked a slowdown from the previous month’s 2.3% and missed market estimates of 2.5%, which exerted pressure on the JPY/USD forex pair.
Brazil’s trade surplus rose to $6.96 billion in October, from $2.99 billion in the previous month. The latest reading coming in above market expectations of $6.2 billion sent the BRL/USD pair higher in forex trading this morning.
Eurozone’s retail sales declined by 0.1% in September, missing market estimates of 0.2%, which exerted pressure on the EUR/USD forex pair.
The Bank of Mexico lowered its benchmark interest rate by 25 bps to 7.25%. This came in-line with expectations and sent the MXN/USD pair slightly higher in forex trading this morning.
China’s current account (1300 UAE Time), Singapore’s foreign exchange reserves (1315 UAE Time), India’s foreign exchange reserves (1530 UAE Time), Brazil’s PPI (1600 UAE Time), Mexico’s inflation rate (1600 UAE Time), auto exports (1600 UAE Time) and auto production (1600 UAE Time), Russia’s foreign exchange reserves (1700 UAE Time), Turkey’s Treasury cash balance (1830 UAE Time), US Michigan consumer sentiment (1900 UAE Time), Michigan consumer expectations (1900 UAE Time), Michigan inflation expectations (1900 UAE Time), Baker Hughes oil rig count (2200 UAE Time) and Baker Hughes total rigs count (2200 UAE Time), as well as Argentina’s industrial production (2300 UAE Time).
ADSS
8th floor, CI Tower
Corniche Road
PO Box 93894
Abu Dhabi
United Arab Emirates
Trading Services
ts@adss.com
+971 2 657 2414
Investing in CFDs involves a high degree of risk that you will lose your money due to the use of leverage, particularly in fast moving markets, where a relatively small movement in the price can lead to a proportionately larger movement in the value of your investment. This can result in loses that exceed the funds in your account. You should consider whether you understand how CFDs work and you should seek independent advice if necessary.
ADS Securities L.L.C – S.P.C (“ADSS”), a limited liability company – sole proprietorship company incorporated under United Arab Emirates law. Registered under Commercial License No.1190047. ADS Securities L.L.C S.P.C is regulated and authorised in the UAE by the Capital Market Authority (CMA) under Category 1 License No.305027 (Trading Broker, Trading and Clearing Broker, Trading Broker in the International Markets, Trading Broker of OTC Derivatives and Currencies in the Spot Market, Financial Products Dealer) and Category 5 License No.20200000217 (Introduction). Registered Office: 8th Floor, CI Tower, Corniche Road, P.O. Box 93894, Abu Dhabi, United Arab Emirates.
The information presented is not directed at residents of any particular country outside the United Arab Emirates and is not intended for distribution to, or use by, any person in any country where the distribution or use is contrary to local law or regulation.
ADSS is an execution only service provider and does not provide advice. ADSS may publish general market commentary from time to time. Where it does, the material published does not constitute advice, or a solicitation, or a recommendation to a transaction in any financial instrument. ADSS accepts no responsibility for any use of the content presented and any consequences of that use. No representation or warranty is given as to the completeness of this information. Anyone acting on the information provided does so at their own risk.
